ARTICLE | Clinical News
Faslodex fulvestrant regulatory update
September 20, 2010 7:00 AM UTC
FDA approved a 500 mg dose of intramuscular Faslodex fulvestrant from AstraZeneca to treat hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression after ant...